Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases (vol 18, 1198, 2018)

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases (vol 18, 1198, 2018)

10.1186/s12885-018-5215-7

Saved in:

Bibliographic Details
Main Authors:	Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel SW, Lim, Darren Wan-Teck
Other Authors:	DUKE-NUS OFFICE OF ACAD & CLINICAL DEVT
Format:	Others Erratum
Language:	English
Published:	BMC 2022
Subjects:	Science & Technology Life Sciences & Biomedicine Oncology
Online Access:	https://scholarbank.nus.edu.sg/handle/10635/218599
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	National University of Singapore
Language:	English

Similar Items

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
by: Tan, Wan-Ling, et al.
Published: (2022)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
by: Lai, Gillianne GY, et al.
Published: (2024)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
by: Park, Keunchil, et al.
Published: (2022)

EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: A retrospective database analysis of potential drug interaction
by: Kumarakulasinghe, N.B, et al.
Published: (2020)

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
by: Chua, Khi Pin, et al.
Published: (2024)

Clinical Benefit of EGFR-TKI in Management of NSCLC
by: Siprianus Ugroseno Yudho Bintoro
Published: (2017)

Effects of single nucleotide polymorphisms on the binding of afatinib to EGFR : a potential patient stratification factor revealed by modeling studies
by: Kannan, Srinivasaraghavan, et al.
Published: (2020)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020)

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
by: Suresh S. Ramalingam, et al.
Published: (2020)

Response Evaluation on Single Common and Uncommon EGFR Mutation on First-Generation EGFR-TKI Therapy in NSCLC Patients
by: Rena Arusita Maranatha, et al.
Published: (2021)

Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
by: Popat S.
Published: (2023)

Role of BIM deletion polymorphism and BIM expression as predictive biomarkers to maximize the benefit of EGFR-TKI treatment in EGFR-Positive NSCLC
by: Pimpin Incharoen, et al.
Published: (2020)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
by: Goh, Kah Yee, et al.
Published: (2024)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
by: Kannan, Srinivasaraghavan, et al.
Published: (2017)

NSCLC PATIENTS WITH BOTH WILDTYPE EGFR AND HIGH CD151 EXPRESSION HAVE POORER DISEASE OUTCOME
by: Wong, Amanda, et al.
Published: (2019)

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
by: Nahar, Rahul, et al.
Published: (2018)

Comparison between Vinorelbine–Carboplatin and Vinorelbine–Cisplatin in Stage III–IV EGFR Mutations-Negative NSCLC
by: Laksmi Wulandari, -, et al.
Published: (2022)

Cost-effectiveness analysis of egfr mutation testing and afatinib versus gemcitabine-cisplatin as first-line therapy for advanced non-small-cell lung cancer in china
by: You, R., et al.
Published: (2021)

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective
by: Tan, P.-T, et al.
Published: (2020)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
by: Kannan, S, et al.
Published: (2020)

Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
by: Chang, Gee-Chen, et al.
Published: (2022)

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR plus non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
by: Ma, Jun, et al.
Published: (2024)

Brief Report: Droplet Digital Polymerase Chain Reaction Versus Plasma Next-Generation Sequencing in Detecting Clearance of Plasma EGFR Mutations and Carcinoembryonic Antigen Levels as a Surrogate Measure
by: Saw, Stephanie PL, et al.
Published: (2024)

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer
by: Saifon W.
Published: (2023)

HCC-derived EGFR mutants are functioning, EGF-dependent, and erlotinib-resistant
by: Natthaporn Sueangoen, et al.
Published: (2020)

Highly sensitive EGFR mutation detection by specific amplification of mutant alleles
by: Nalin Leelatian, et al.
Published: (2018)

Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset
by: Byoung Chul Cho, et al.
Published: (2018)

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
by: Nahar, R, et al.
Published: (2020)

PERBANDINGAN RESPONS KEMOTERAPI DAN EFEK SAMPING PENGGUNAAN PLATINUM DOUBLET KOMBINASI EGFR TKI DENGAN PLATINUM DOUBLET TUNGGAL PADA PENDERITA NSCLC MUTASI GEN EGFR PROGRESSIVE DISEASE
by: Edward Pandu Wiriansya
Published: (2017)

Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung Cancer
by: Ho, Y.S, et al.
Published: (2020)

Healthcare coverage affects survival of EGFR-mutant Thai lung cancer patients
by: Khiewngam K.
Published: (2023)

Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301
by: Reungwetwattana T.
Published: (2023)

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)
by: Lim, E.H., et al.
Published: (2011)

Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC)
by: Lim, E.H., et al.
Published: (2014)

Molecular diagnostics in advanced NSCLC: Trying to maximize a non-ideal situation
by: Lim, E.H., et al.
Published: (2016)

Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities
by: Ho, Teresa Lai Fong, et al.
Published: (2023)

Domain-specific p53 mutants activate EGFR by distinct mechanisms exposing tissue-independent therapeutic vulnerabilities
by: Ho, Teresa Lai Fong, et al.
Published: (2023)

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
by: Tony Mok, et al.
Published: (2018)

Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
by: Tony Mok, et al.
Published: (2018)

Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies (Targeted Oncology, (2023), 18, 1, (9-24), 10.1007/s11523-022-00941-7)
by: Popat S.
Published: (2023)